Targeting ALK in neuroblastoma--preclinical and clinical advancements. - Wikidata - awgldk - TriplyDB

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

http://www.wikidata.org/entity/Q36933081

about

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy Pediatric solid tumor genomics and developmental pliancy Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices.Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.Therapeutic targets for neuroblastomas.Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Detection of tumor ALK status in neuroblastoma patients using peripheral blood.Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo.Drug discovery in paediatric oncology: roadblocks to progress.Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group Targeting developmental pathways in children with cancer: what price success?Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas Neuroblastoma and MYCN Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.ALK: a tyrosine kinase target for cancer therapy.Neuroblastoma treatment in the post-genomic era.Emerging drugs for neuroblastoma.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.New immunotherapeutic strategies for the treatment of neuroblastoma.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma Equal access to innovative therapies and precision cancer care.Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.Advances in emerging drugs for the treatment of neuroblastoma.Genetic susceptibility to neuroblastoma.Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma

P2860

Q26849503-F0704751-2A1D-43A7-B9ED-94032AAFE45D Q27023560-FCE7FF5C-4BB4-4C14-9B21-718795A87430 Q27319837-E1FBC2A9-20F0-49E7-B3F9-CCC6FF84199F Q27673414-89E8D8C5-DC28-44DC-BEBC-F92D8C259B97 Q27853323-D2ABE971-CC98-4BF1-B0A4-07157780D3F3 Q30365308-78CE6C6E-F2D6-4442-9604-C607B8577A50 Q30426051-CF7A9B73-AF02-4B3E-BE12-0A9988199E3F Q33737740-0FEAD48E-B266-444E-999D-E9CD51DC09EF Q33903573-E459380D-8236-41FF-AB0E-36307998E78B Q34032495-DBDAD645-86B1-4507-843A-B8CA0E9BDB96 Q34221605-9EBABDD2-6AC1-4FEC-BB8B-C45D975B57EE Q34560877-37B6B7EC-5C3D-4666-A82E-BA5939EA7973 Q35049970-C7E1440C-245F-41AE-879B-CA07392012A5 Q35131527-0F191B1E-DF6A-4990-AF3B-6C009BD53FD6 Q35283020-FC2A6AFC-6F16-45AB-B4FA-11A7BC36DAAB Q35469393-D6891825-0362-4E51-AA98-3651CD0920E5 Q35598158-32EC06F3-7FEA-48B5-9E26-236A202A255D Q36262295-7277E15C-6EF3-49FE-A0A5-53710EF5317A Q36378105-1B82A307-A27E-46FF-BB1D-ADA11A10A720 Q36380013-BC7B5C6C-803C-4722-801E-63CDDEBF81B5 Q36905620-5C6C9647-F5DD-4836-9F30-DE32748D8CB7 Q37065337-F6FDCA6D-357F-4F4F-AAF9-4ED8371E1E9E Q37201479-36B0149F-AF15-43E8-9BCF-67A696C944C3 Q37286919-A923016F-542A-4BF6-A7C1-92F8C96120E8 Q37518624-6C7D7439-8077-4428-A743-A503CBB76F23 Q37633731-EB0B8AB5-FA8B-4D1E-B64F-89AB21F14612 Q38108399-6649574E-96CC-4ACE-9711-5EABB7268DEE Q38161274-D1194B19-9386-423B-847D-C53C8AD29953 Q38389316-30BFAD1C-88A3-44ED-B9C4-0A33469EE94A Q38625880-89B09C53-B81B-44BB-BCE1-886DC2E86D9B Q38707447-C301F08E-D974-417B-B7BC-4331A398C383 Q38741543-668F9E41-C13D-4A9B-A7A7-1D64C8A9DA61 Q38784010-4D45A674-96CC-4453-A883-7D36BD033ADC Q38800617-BB768085-B12C-4302-BAA7-2F77BB6DEDCC Q39051444-00EBBF93-34FF-44EC-8FED-3EB1B06DB40E Q39158415-F0E31101-375E-4260-A5A0-1E3BC922C806 Q39273903-85DB8E8B-5E0A-4D70-A8C4-76E8CD1AC3AD Q40991136-EEF9C586-F16D-4301-95AC-13B5F056F16E Q40999620-D46BBE64-C2AC-4395-8A4E-D2FBFE72CCB4 Q41738897-9F267B6B-3F93-47A6-B813-A7AF7A78F89E

P2860

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

http://www.wikidata.org/entity/Q36933081

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

@en

type

label

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

@en

prefLabel

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

@en

P1433

Q36933081-98BE2D5E-5D26-435F-AF42-6CCA1F49D890

P1476

Q36933081-C85B0E7C-0993-4ADE-A194-3BD92F27F3A8

P2093

Q36933081-0275D120-6365-4726-85DF-178AED3E4DBA

Q36933081-76832153-7BE9-4CDB-AE61-B2CAE32D2D42

P2860

Q36933081-022CA447-334B-4748-9052-D73965EBEFFA

Q36933081-04F1DD56-D355-4D51-AD25-DE4F8286C6AD

Q36933081-05162DFA-ECCD-4053-8006-F78EF963EF22

Q36933081-0C2A6115-02DF-46B3-8546-B37B9A9AF050

Q36933081-11BCF99C-0361-43B9-B084-0F2927AE7B29

Q36933081-18BBFA26-F73C-45DA-94FA-DE8BDC9FF9E3

Q36933081-1A315AD1-25B1-42C9-962E-918F93219777

Q36933081-1ABB8511-A604-4342-BB09-32EDB8765CA4

Q36933081-1AC2934B-9C6E-47ED-BB5F-672095522778

Q36933081-1B021C37-A3FA-4EE1-A9C4-790B120A5541

P304

Q36933081-36D1E55E-071E-44DB-96E6-F05B68B6791D

P31

Q36933081-2FCDA5A7-1C87-40EC-901E-0BC606EA86B2

P356

Q36933081-3656AAFD-EA16-481C-9E43-D885493AC0E6

P407

Q36933081-A5DA58FE-01B2-455C-BB55-D01B2E58E0D2

P433

Q36933081-18693416-8A12-4B85-B827-675FECB76EDE

P478

Q36933081-4B85C134-0C23-4A7F-B635-1B63A8F1E1FE

P577

Q36933081-A78A2B4C-742E-4688-8232-134B22024A6A

P698

Q36933081-AF2C4E25-40E3-48C6-9406-323506EEC9E4

P932

Q36933081-7FD2ACFD-F7F4-45AD-921D-746183144CF8

P356

NRCLINONC.2012.72

P1433

Nature Reviews Clinical Oncology

P1476

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

@en

P2093

Erica L Carpenter

http://www.w3.org/2001/XMLSchema#string

Yael P Mossé

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase: signalling in development and disease

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

The biology and treatment of EML4-ALK non-small cell lung cancer

Identification of ALK as a major familial neuroblastoma predisposition gene

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

P304

391-399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2012.72

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22585002

http://www.w3.org/2001/XMLSchema#string

P932

3683972

http://www.w3.org/2001/XMLSchema#string